INTRODUCTION
Patients with T1 to T2, lymph node-negative (N0) breast cancer who are undergoing mastectomy typically are considered to be at low risk of locoregional disease recurrence (LRR), and postmastectomy radiotherapy (PMRT) is not a routine part of treatment. 1 Indications for PMRT in patients with T1 to T2N0 disease believed to be at an increased risk of LRR are controversial due to a lack of consensus regarding what constitutes "high risk" in the absence of lymph node metastases. [1] [2] [3] [4] [5] [6] [7] To the best of our knowledge, the most consistently described characteristics associated with LRR in retrospective studies include age <40 years, the presence of lymphovascular invasion (LVI), tumor size, and high nuclear grade, with rates of LRR reported to be as high as 20% in women with multiple risk factors. 1, 4 Multifocal or multicentric cancer also has been associated with an increased risk of LRR. 8, 9 Although all tumor locations drain primarily to the axilla, tumors in the medial or central breast and those with involvement of internal mammary lymph nodes have been suggested to have a worse prognosis. 10, 11 It is interesting to note that these studies included patients who were treated primarily from the 1980s to the mid-2000s and did not reflect the use of modern systemic therapies. [1] [2] [3] [4] [5] [6] [7] More recently, 10-year results of the National Cancer Institute of Canada Clinical Trials Group MA20 and the European Organization for Research and Treatment of Cancer (EORTC) 22922-10925 randomized controlled trials demonstrated improved disease-free survival with the addition of regional lymph node irradiation to whole-breast RT for early-stage breast cancers in patient populations that included "high-risk" patients with N0 disease. 12, 13 The MA20 trial randomized patients undergoing lumpectomy for T1 to T3 disease, including both patients with lymph node-positive disease and those with lymph node-negative disease with "high-risk" features, defined as a tumor size >5 cm, grade 3 histology as defined by the modified Bloom-Richardson-Elston grading system, 14 estrogen receptor (ER) negativity, or LVI. 12 The EORTC 22922-10925 trial randomized patients undergoing either lumpectomy or mastectomy for T1 to T3 cancers, including both those with lymph node-positive disease and patients with lymph node-negative disease who were deemed high risk due to a central or medial tumor location. 13 Patients with lymph node-negative disease comprised 10% and 44%, respectively, of the MA20 and EORTC study populations. Although only 24% of patients in the EORTC trial were treated with mastectomy, there is no reason to believe that the benefit of lymph node irradiation is related to the use of lumpectomy or mastectomy. 12, 13 To the extent of our knowledge, the impact of these high-risk disease characteristics on LRR in patients with T1 to T2, lymph node-negative cancers who are undergoing mastectomy and who are treated with modern systemic therapy remains uncertain. Herein, we sought to evaluate locoregional control in a contemporary study cohort.
MATERIALS AND METHODS
After Institutional Review Board approval, all women diagnosed with T1 to T2, lymph node-negative (T1-T2N0) invasive breast cancer with at least 1 high-risk feature who underwent mastectomy at Memorial Sloan Kettering Cancer Center between January 2006 and December 2011 were identified. Lymph node negativity was defined as the absence of any tumor, including isolated tumor cells or micrometastases, in the sentinel lymph nodes (SLNs). SLN processing was uniform throughout the study period and included serial sections at 2 levels approximately 50 mm apart in all SLNs that were negative on initial staining with hematoxylin and eosin. Immunohistochemical staining for cytokeratin and an additional staining with hematoxylin and eosin were performed on deeper levels. High-risk features were defined as age <40 years at the time of diagnosis, multifocal or multicentric tumor, the presence of LVI, central or medial tumor location, and high nuclear grade. Patients with recurrent disease, those with bilateral tumors, and those who received neoadjuvant chemotherapy were excluded.
Standard clinicopathologic data were collected, including patient age at the time of diagnosis, clinical presentation of disease, tumor size, nuclear grade, subtype, and final tumor pathologic findings. Rates of the administration of RT and systemic therapies, and the regimens used, were assessed. The primary outcome of interest was the LRR rate. LRR was defined as a biopsy-proven recurrence of disease in the ipsilateral chest wall or in the ipsilateral regional lymph nodes including the axillary, internal mammary, or supraclavicular lymph nodes. Development of metastatic disease at any other site was considered a distant disease recurrence.
Statistical Analysis
Continuous variables were compared using the Wilcoxon test, and categorical variables were compared using the chi-square or Fisher exact tests. Crude events were reported; however, all analyses were conducted using time-to-event methods that accounted for censoring and follow-up time. Kaplan-Meier methods were used to analyze rates of LRR, and the log-rank test was used to examine the associations between categorical risk covariates and LRR, whereas Cox regression analysis was used for continuous variables and to estimate hazard ratios (HRs). The number of high-risk features ranged from 0 to 5. The risk score was calculated by adding the presence or absence of 5 risk factors in patients with complete data with equal weight for each factor. For all competing risk analyses that differentiated between types of disease recurrence, the first event was counted as the primary event, and deaths due to any cause were analyzed with the distant recurrence category as per the Standardized Definitions for Efficacy End Points (STEEP) system for breast cancer trials. 15 The Gray test was used to evaluate associations. All statistical analysis was performed using SAS statistical software (version 9.2; SAS Institute Inc, Cary, NC) and R statistical software (version 3.1.1; R Foundation, Vienna, Austria [https://www.r-project.org/]). Any P value < .05 was considered to be statistically significant.
RESULTS
From January 2006 to December 2011, a total of 672 women with T1 to T2N0 invasive breast cancer and at least 1 high-risk feature underwent mastectomy. Of these patients, 187 (28%) had a single high-risk feature: 21 patients (3%) were age < 40 years, 132 patients (20%) had multifocal or multicentric tumors, and 34 patients (5%) demonstrated LVI. More than 1 high-risk feature was noted among 449 patients (67%), with 2, 3, and 4 risk factors observed in 268 patients (40%), 146 patients (22%), and 35 patients (5%), respectively. The remaining 36 patients (5%) were excluded from the risk analysis due to an unknown nuclear grade.
PMRT was received by only 15 of the patients with high-risk lymph node-negative disease (2%) during the 6-year study period. The remaining 657 patients who were treated without PMRT comprised the study cohort. Clinicopathologic characteristics are summarized in Table 1 . The median patient age was 49 years, the median tumor size was 1.4 cm, and the majority of patients had ductal histology (86%) and ER positive (ER1) disease (78%). SLN biopsy (SLNB) alone was performed in 641 patients (98%), with a median of 4 SLNs removed (range, 1-15 SLNs). The remaining 16 patients underwent axillary lymph node dissection for failed mapping (3 patients) or by physician choice (13 patients). Adjuvant systemic therapy was received by 565 patients (86%): 268 patients (41%) received both chemotherapy and endocrine therapy, 90 patients (14%) received chemotherapy alone, and 207 patients (32%) received endocrine therapy alone. A total of 86 of the 657 evaluable patients (13%) received no systemic therapy, and receipt of treatment was unknown in 6 patients. Of the 358 patients who received chemotherapy, 181 (51%) were treated with doxorubicin, cyclophosphamide, and paclitaxel; 137 (38%) received cyclophosphamide, methotrexate, and 5-fluorouracil; 38 (11%) received docetaxel and cyclophosphamide; and 2 patients were treated with other regimens on trial protocols. Of 123 patients with tumors that overexpressed human epidermal growth factor 2 (HER21), 86 (70%) also received trastuzumab. Among 513 patients with ER1 disease, 466 (91%) received endocrine therapy.
After a median follow-up of 5.6 years (range, 0-115 months), 31 patients in the study cohort (4.7%) had experienced LRR, 22 of whom developed isolated LRR and 9 of whom experienced simultaneous (diagnosed within 1 month) LRR and distant disease recurrence. Twentythree patients (3.5%) had developed distant disease recurrence alone. The median time to LRR among the 31 patients who experienced an LRR was 33 months (range, 1-79 months). The LRR was located within the chest wall alone in 14 patients (45%), synchronous chest wall and axillary lymph nodes in 3 patients (10%), axillary lymph nodes alone in 9 patients (29%), supraclavicular lymph nodes alone in 2 patients (6%), internal mammary lymph nodes alone in 1 patient (3%), synchronous axillary and supraclavicular lymph nodes in 1 patient (3%), and synchronous axillary and internal mammary lymph nodes in 1 patient (3%). Overall, local disease recurrence was observed in 17 patients (2.6%) and regional disease recurrence was noted in 17 patients (2.6%). Table 2 summarizes the clinicopathologic characteristics of the 31 patients who experienced LRR. These patients had a median age of 49 years and a median tumor size of 1.6 cm, and the majority had ER1 (81%) ductal (84%) cancer. Systemic therapy as recommended was not received by 10 of the patients with LRR (32%), including chemotherapy for 3 patients (2 of whom had HER21 disease) and endocrine therapy for 7 patients. The crude rates of LRR among those with 1, 2, 3, or 4 high-risk features were 3.8%, 5.3%, 4.9%, and 9.4%, respectively. The HRs and P values that evaluated the relationship between patient and tumor characteristics and LRR are shown in whereas age, histology, nuclear grade, receptor status, LVI, multifocal or multicentric tumor, and location of the tumor were not found to be associated with LRR (all P > .05). Receipt of systemic therapy decreased LRR (HR, 0.40; 95% CI, 0.17-0.92 [P 5 .03]). A KaplanMeier curve of LRR by the number of high-risk features (Fig. 1 ) demonstrated no significant relation between LRR and the number of risk factors when comparing patients with 1 versus 2 versus 3 versus 4 high-risk features (P 5 .54). The 5-year LRR-free survival for patients with 1 risk factor was 96% (95% CI, 0.91-0.98), whereas it was 95% for those with 2 risk factors (95% CI, 0.91-0.97), 95% for those with 3 risk factors (95% CI, 0.90-0.99), and 92% for those with 4 or 5 risk factors (95% CI, 0.71-0.98). There was no difference with regard to the cumulative incidence of events with an increasing number of risk factors noted among any type of disease recurrence: isolated LRR (P 5 .77), combined LRR and distant disease recurrence (P 5 .6), and distant events (P 5 .11) (Fig. 2) . 
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DISCUSSION
The results of the current study demonstrate a low LRR rate of 4.7% at a median follow-up of 5.6 years in a large, contemporary cohort of patients with T1 to T2, lymph node-negative breast cancer with high-risk disease features who were treated with mastectomy and systemic therapy, without PMRT. Tumor size was found to be significantly associated with LRR (HR, 1.70), and the LRR rate was decreased with the receipt of systemic therapy (HR, 0.40); however, no significant increase in LRR was observed with an increasing number of high-risk features (P 5 .54). The LRR rate observed in the current study is lower than past rates of 5.2% to 9.2% noted in similar populations of patients with lymph node-negative disease who were treated without PMRT (Table 4) . 1, [3] [4] [5] [6] 16 Although PMRT has been shown to reduce rates of LRR, a metaanalysis from the Early Breast Cancer Trialists' Collaborative Group demonstrated an absolute reduction in LRR of only 4% among patients with lymph node-negative breast cancer who were treated with mastectomy and PMRT, and no improvement in 15-year survival. 16 The benefit of PMRT in patients with T1 to T2N0 breast cancer with 1 or multiple defined high-risk features remains controversial. The potential for a higher risk of LRR conferred by these characteristics was demonstrated in retrospective studies of patients treated before the widespread use of systemic therapy in those with lymph node-negative breast cancer.
1-7 Sharma et al found that age 40 years was an independent predictor of LRR in a study of 753 patients with T1 to T2N0 breast cancer who were treated with mastectomy without PMRT from 1997 to 2002. 3 In a population of 1136 similar patients treated from 1980 to 2004, Abi-Raad et al found young age, tumor size >2 cm, and LVI to be predictive of LRR. 1 Truong et al demonstrated higher risk with LVI, young age, high grade, and tumor size >2 cm among 1505 patients with breast cancer treated from 1989 to 1999. 4 Similarly, in a cohort of 502 patients treated from 1990 to 2004, Yildirim and Berberoglu found tumor size >2 cm, LVI, and high grade to be predictive of LRR. 5 However, conflicting results also have been reported. Voogd et al found no influence of age on LRR in patients undergoing mastectomy for lymph node-negative disease, 17 whereas Janni et al demonstrated no relation between LRR and tumor grade or size among patients with T1 to T2N0 disease who underwent mastectomy. 18 Although age < 40 years was found to be associated with a lower rate of recurrence-free and overall survival for patients with HER21 disease who were treated between 1986 and 1992, this difference was not observed in the cohort treated between 2004 and 2007, and no difference in . Combined LRR and distant disease recurrence: 9 events (Gray test P 5.6). Deaths due to any cause were included in the "distant" category as per the Standardized Definitions for Efficacy End Points (STEEP) system for breast cancer trials.
14 CIF indicates cumulative incidence function.
outcome based on age was noted in the study by Sheridan et al, 19 suggesting that effective systemic therapy many diminish the effect of the poorer prognostic profile often noted in younger women. The only disease feature found to be predictive of LRR in the current study was tumor size (HR, 1.70; 95% CI, 1.26-2.29 [P 5 .006]), whereas all other high-risk features studied were not found to be predictive of LRR (all P > .05).
The low LRR rate observed in the current study most likely reflects the results of present-day practice, in which the vast majority of patients with breast cancer receive systemic treatment tailored to individual tumor biology. This is supported by the observed association between systemic therapy and disease-free survival noted herein. Adjuvant endocrine and/or chemotherapy were received by 86% of patients in the current study compared with 38% to 77% of patients in previous studies examining this question. 1, [3] [4] [5] Systemic targeted therapies have been demonstrated in randomized trials to reduce both local and systemic disease recurrence. [20] [21] [22] In a study of 86,598 patients treated in phase 3 trials between 1990 and 2011, Bouganim et al found that LRR as a percentage of all recurrences decreased from 30% to 15%, independent of patient age, use of RT, or treatment with lumpectomy or mastectomy. 23 It is important to note that as improvements in systemic therapy lead to improvements in distant disease-free or overall survival, parallel reductions in local disease recurrence are observed. For example, although chemotherapy alone is reported to reduce the LRR rate by 30%, the addition of trastuzumab in patients with HER2 overexpressing disease leads to a further reduction of 25% to 53%. 21, 24, 25 This concept is supported by the current study finding that although the rate of LRR did increase to 9.4% in patients with 4 risk factors, this rate was significantly lower than the historical rate of 20% in patients with multiple risk factors reported in older study cohorts. 1, 4 The importance of systemic therapy was noted in the current study, with a significant reduction in LRR observed with the receipt of adjuvant systemic treatment. Among patients who experienced LRR, recommended chemotherapy was not received by 3 patients (10%), and 7 of 25 patients with ER1 disease with LRR (28%) declined endocrine therapy. In an era in which tumor biology is recognized as a principal determinant of disease recurrence and indications for systemic therapy in low-risk patients have expanded, re-evaluation of the criteria for the use of PMRT is appropriate.
The majority of recurrences in the current study cohort involved the chest wall, which is consistent with previously demonstrated patterns.
1 However, 8 of 22 isolated LRR events involved the axillary lymph nodes alone. This is a higher percentage than was anticipated, compared with a very low 0.12% rate of axillary lymph node recurrence observed in a study including 2340 patients with negative SLNs who underwent SLNB alone. 26 We hypothesize that this may be due in part to false-negative SLNBs, because 7 of the 8 patients underwent SLNB alone. A meta-analysis including 9220 patients with pathologically negative SLNs who underwent completion axillary lymph node dissection reported a crude overall false- negative rate of 8.6%. 27 However, the false-negative rate has been shown to decrease to <5% with the retrieval of multiple lymph nodes, 28 and a median of 4 lymph nodes (range, 2-17 lymph nodes) were obtained among the 8 patients in the current study cohort with isolated axillary lymph node recurrence.
Recent support for comprehensive lymph node irradiation has been provided from randomized controlled trials demonstrating a reduction in regional (lymph node) disease recurrence with this approach, although this was observed in study populations composed largely of patients with lymph node-positive disease. 12, 13 The 10-year results of the EORTC 22922 trial demonstrated a significant improvement in disease-free survival with the addition of internal mammary and medial supraclavicular irradiation to whole-breast RT. 13 Patients with T1 to T2N0 disease with high-risk features who were undergoing mastectomy comprised only a small minority of the heterogeneous study population. Although the location of the LRR was not provided in this subset of patients, in the study arm treated with comprehensive irradiation, the rate of regional lymph node recurrence was reduced to 2.7% from 4.2% in the control arm of patients treated with whole-breast irradiation only. 13 We observed a regional lymph node recurrence rate of 2.6% in the current study, suggesting a limited benefit to adding lymph node irradiation in this population, given the already very low rates of lymph node recurrence without any RT, despite the presence of high-risk disease features.
There are limitations to the current study. It is a retrospective review and therefore potentially subject to selection bias. However, only 15 patients (2%) who were treated during the study period underwent PMRT, making it unlikely that the study population is a particularly favorable cohort. In addition, the number of patients with 4 risk factors was small, thereby limiting the ability to assess LRR in this subgroup. However, this reflects the distribution of risk factors in a lymph node-negative population. A group of high-volume, dedicated breast surgeons performed the surgeries on these patients, and this also may have contributed to the low rates of LRR that were observed; therefore, the generalizability of the current study results is uncertain.
Conclusions
The overall low crude LRR rate of 4.7% at a median of 5.6 years of follow-up in the current large, contemporary cohort of patients with T1 to T2 lymph node-negative disease with high-risk features who were treated with mastectomy demonstrates that excellent locoregional control can be obtained in this population without the use of PMRT. This is inarguably affected by improvements in, and the increased use of, systemic therapies tailored to individual tumor biology, with an observed significant association between systemic therapy and LRR-free survival. Given the known possible complications of RT, appropriate risk stratification to identify those patients who would benefit the most from PMRT is crucial. Although increasing tumor size did appear to confer a higher risk of LRR in these patients, all of the other highrisk disease features assessed, either independently or together, did not. The results of the current study strongly suggest that features traditionally believed to convey an increased risk of LRR, in the setting of appropriate adjuvant systemic treatment, do not by themselves support the use of PMRT in patients with T1 to T2N0 disease who are undergoing mastectomy. Results from the ongoing Selective Use of Postoperative Radiotherapy after Mastectomy (SUPREMO) trial, which includes a subset of patients with lymph node-negative, high-risk disease, will provide important information regarding the risks and benefits of PMRT in this population.
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